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doi:10.1016/j.jtcvs.2004.03.017The objectives of every cardiac operation, whether adult or pediatric,are technical success and absence of iatrogenic injury from inade-quate myocardial protection. To obtain the best results, the surgeonshould select a method of protection only after learning how thecardioplegic method was developed, as well as how to benefit fromits advantages, and how to avoid inappropriate use by recognizing
the disadvantages. The choice for protection is similar to the selection of a structural
technique for surgical repair of an underlying cardiac lesion. Failure of either
modality is unacceptable, because both are equally important if the patient is to
receive the full benefit from the surgical correction. Improved myocardial protection
is not a phase of surgical development; it is intrinsic to the repair of congenital
cardiac defects.
Despite major advances in the technical aspects of surgical repair, pediatric
myocardial protective techniques remain relatively unchanged. Moreover, there are
currently few articles in the major journals on pediatric myocardial protection. This
would imply that current techniques provide optimal and complete preservation of
the pediatric heart and that there is little need for further research to improve
protection methods. However, pediatric patients continue to need mechanical assist
devices, as well as prolonged inotropic support or an open chest despite a “techni-
cally perfect repair.” Moreover, perioperative myocardial damage with low cardiac
output remains the most common cause of morbidity and death after repair of
congenital lesions.1-3 Cardiac damage from inadequate myocardial protection can
prolong hospital stay and result in delayed myocardial fibrosis, leading to cardiac
dysfunction months to years later.1 Protection of the immature heart is further
complicated by a reduced response to inotropic agents relative to the adult heart.2-4
Thus preservation of myocardial function in immature hearts assumes even greater
importance, because a perioperative insult is both less well tolerated and more
difficult to treat.
In general, most changes in pediatric myocardial protection have been derived
from the adult cardiac experience. However, in view of the structural, functional,
and metabolic differences, extrapolation of adult cardioprotective strategies to the
pediatric patients is fundamentally imprudent and potentially harmful.2-7 Myocar-
dial protective strategies and cardioplegia solutions must be studied in the immature
heart if pediatric protection is to be truly optimized.
In this issue, Modi and associates8 report a randomized clinical trial comparing
crystalloid with blood cardioplegia in pediatric patients. Demonstrating differences
between cardioplegic techniques is often difficult in the clinical setting because,
unlike in the experimental laboratory where variables can be precisely controlled
and measured, patients are not uniform, and the measurements of damage are less
precise. In the experimental laboratory all hearts are subjected to the same prein-
tervention stress, they undergo identical periods of ischemia, their anatomy is not
altered, and postoperative measurements are precise and sensitive to detect damage.
This makes it easy to demonstrate differences in protection strategies. In contrast,
hearts in clinical studies are all different before surgery, they are anatomically
altered (repaired), during surgery their crossclamp times are varied, and the post-
operative measurements are far less precise. This makes it much more difficult to
demonstrate clinical differences unless they are profound, even though significant
myocardial damage may have occurred.





LAnother problem in assessing clinical adequacy of myo-
cardial protection is when to examine patient outcome and
cardiac function, because direct assessment of myocardial
damage is much more difficult than in the experimental
laboratory. Ideally we should examine cardiac function not
only in the perioperative period but several years later. A
heart with nearly normal preoperative function may come
off bypass, and the patient may go home despite rather
extensive myocardial damage, giving the surgeon the false
impression the protection was excellent. Nonetheless, peri-
operative myocardial damage may affect the long-term out-
come and lead to late cardiac dysfunction months to years
after surgical repair.1 This may be particularly important in
patients who require several surgeries to correct their de-
fects and may explain, for example, the late cardiac dys-
function in patients with hypoplastic left heart syndrome
following their Fontan procedure.
Despite these limitations, the data presented by Modi and
associates8 support several experimental and clinical studies
and demonstrate that blood cardioplegia with a warm reper-
fusate provides better protection than crystalloid or cold
blood cardioplegia alone.7,9,10 However, this improvement
in protection was only seen in cyanotic patients. This is not
particularly surprising, because hypoxic hearts are less tol-
erant of surgical ischemia and more dependent on the
method of protection.2,5,7,9Nevertheless, it is surprising that
the study only examined relatively older, low-risk pediatric
patients with essentially normal cardiac function. They ex-
cluded neonates and patients with hemodynamic instability,
cases in which clinical differences in protection strategies
are more likely to be identified. These are also the patients
most dependent on optimal protection, as well as the group
most likely to exhibit differences in protection strategies
relative to adult (mature) hearts. Therefore they are proba-
bly the most important patients to include in studies of
pediatric cardioprotection techniques.
In any investigation of myocardial protection, it is criti-
cal that the composition of the cardioplegia solution and the
method of delivery be closely examined in interpreting the
results. In their study, Modi and associates8 used St
Thomas’ Hospital solution (Plegisol) cardioplegia, either
alone or mixed with blood, to compare crystalloid to blood
cardioplegia with or without a warm reperfusate. However,
these cardioplegic formulations may not provide an optimal
test of blood versus crystalloid cardioplegia. Plegisol was
specifically developed to work best as a crystalloid solution,
with the constituents adjusted to provide optimal protection
at these levels.2,11 Likewise, blood cardioplegic solutions
were formulated to provide the ideal levels of the various
components only after they are mixed with blood.1 In other
words, blood cardioplegia is not just any crystalloid solution
added to blood. Mixing Plegisol with blood alters the con-
centrations of its components and as such may not provide
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crystalloid solution, or as cardioplegia solutions designed to
be mixed with blood. Could the lack of difference seen by
Modi and associates8 between blood and crystalloid cardio-
plegia therefore be the result of not using a blood cardio-
plegia solution explicitly developed for that purpose?
Perhaps of more concern is the composition and delivery
of the warm reperfusate used in their study. Just as blood
cardioplegia is not just any cardioplegic solution added to
blood, a warm reperfusate is not just any solution given
warm. Warm reperfusate solutions are specifically formu-
lated to limit the reperfusion injury, and their composition is
vastly different from the cardioplegic solution used for
maintaining myocardial arrest.1,7,10 Reperfusate solutions
are also usually given for at least 4 to 5 minutes, because it
takes time to reverse any ischemic damage that may have
occurred during the period the aorta is clamped.1,7,10 In
contrast, Modi and associates8 delivered their warm reper-
fusate solution for only 2 minutes, and they did not use a
reperfusate solution specifically formulated for this purpose.
This almost certainly limited the effectiveness of this mo-
dality and may be why an even greater benefit was not
observed.
Substrate enhancement of the reperfusate solution is an-
other factor that must be considered. My own group previ-
ously showed that infusing a warm non–substrate-enriched
blood cardioplegic reperfusate for 4 to 5 minutes partially
improved postbypass function and metabolic recovery in
hypoxic piglets undergoing 70 minutes of arrest.10 This
parallels the findings by Modi and associates,8 who did not
use substrate enhancement. However, we subsequently
found that enriching the warm cardioplegic reperfusate with
the amino acids aspartate and glutamate vastly improved its
efficacy, resulting in complete myocardial and metabolic
recovery. 7,10 The increased sensitivity to surgical ischemia
we saw in our hypoxic neonatal piglets also parallels the
findings in cyanotic infants and chronically hypoxic ani-
mals.2,5,12-14 Moreover, Taggart and associates15 recently
demonstrated that both acyanotic and cyanotic infants un-
dergoing corrective surgery are more prone to a reperfusion
injury than are adults. This may explain why Chaturvedi and
coworkers,16 who used a conductance catheter to measure
pressure-volume loops, demonstrated postoperative ventric-
ular dysfunction even in infants undergoing simple atrial
septal defect repair when the heart was protected by cold
cardioplegia alone. Use of this sensitive modality revealed
that myocardial damage may occur even during repair of the
simplest pediatric lesions but it may not be detected by the
usual clinical parameters, such as length of stay or days in
the intensive care unit. Substrate enrichment of the warm
cardioplegic reperfusate may therefore have improved the









LCritical analysis of the adenosine triphosphate (ATP)
data presented by Modi and associates8 raises another con-
cern. Even though most patients were at low risk, postarrest
ATP levels were reduced in every group. This implies that
all three cardioplegic methods provided inadequate protec-
tion. A fall in postreperfusion ATP levels even in low-risk
acyanotic patients with simple lesions demonstrates the
vulnerability of the pediatric heart to ischemia and the need
for improved methods of protection for all pediatric pa-
tients. It implies that although the patients may do fine
clinically, myocardial damage is present. Perhaps if a blood
cardioplegia and warm reperfusate solution specifically de-
veloped for this purpose had been given for an appropriate
time interval, both acyanotic and cyanotic patients would
have had complete return of ATP levels, as occurred even in
severely stressed hypoxic neonatal piglets.7,10
In conclusion, the study by Modi and associates8 is
important, because it is one of only a small number of
studies to investigate myocardial protection strategies in
pediatric patients. Only from studies such as this are we able
to determine the optimal method of protecting the pediatric
heart, instead of blindly, and often uncritically, adopting
untested adult cardioplegic strategies. However, we must
look with caution to the composition of the cardioplegia
solution and the method of delivery in interpreting the
results. It is important that cardioplegic solutions designed
and tested for a specific purpose be used in any study of
cardioplegic protection. These solutions should be delivered
according to established experimental protocols and, most
importantly, the aim must be complete preservation of met-
abolic and functional parameters. A fall in postarrest ATP or
other metabolic levels should be looked at as a protection
failure, in the same way that a residual ventricular septal
defect or atrioventricular valve regurgitation is a technical
failure. Optimal protection is as important as the technical
aspects of the repair, and until we have developed cardiople-
gic techniques that completely avoid myocardial damage,
we must continue to actively investigate new cardioplegia
strategies. Ideally, this important study will spur others to
examine protection strategies in both high- and low-risk
pediatric populations and will reaffirm the importance of
protection in determining the success of a pediatric opera-
tion.
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